AZD8848 是一种选择性的 TLR7 前体药激动剂，用于哮喘和过敏性鼻炎的研究。

AZD8848 is a selective toll-like receptor 7 (TLR7) antedrug agonist which is developed for the research of asthma and allergic rhinitis.

Solid

TLR7

AZD8848 shows good activity against TLR7, with cellular pEC50s of 7.0 and 6.6 for human TLR7 and rat TLR7, respectively.
AZD8848 has an EC50 of 4 nM in the induction of IFNα from human PBMCs and an IC50 of 0.2-1.0 nM for the inhibition of IL-5, irrespective of whether the T cells have been polyclonally stimulated with PHA or via antigen presentation.
AZD8848 is a potent, selective TLR7 agonist antedrug able to inhibit Th2 responses in vitro.
AZD8848 has no activity against human TLR8 or against any of the other human TLRs.
has not independently confirmed the accuracy of these methods. They are for reference only.

AZD8848 (0.1-1 mg/kg; intratracheal) has a good pharmacokinetics in the Brown Norway rat.
AZD8848 (0.3 mg/kg; Intratracheal) suppresses the ovalbumin (OVA) challenge in the rat allergy model.
has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Delaney S, et al. Tolerability in man following inhalation dosing of the selective TLR7 agonist, AZD8848. BMJ Open Respir Res. 2016 Feb 23;3(1):e000113.

In Vitro: DMSO : 25 mg/mL (43.88 mM; ultrasonic and warming and heat to 60°C)配制储备液